Company intelligence / Profile preview

Mireca Medicines

Ownership: Private
Development stage: Preclinical

Overview

Demonstrated proof-of-concept in preclinical IRD-models with favorable safety profile and tolerability window. Upscaled small molecule manufacturing to GMP-grade. Received $989,000 from Foundation Fighting Blindness to advance preclinical development of lead product MM238[3][5].

Therapeutic areas: Ophthalmology
Modalities: Small moleculescGMP-analogs
Industry: Biotech

Drug pipeline

3 assets

CN238

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Previously partnered with Graybug Vision Inc (now CalciMedica Inc) until May 2023[3]

Beyond the preview

Go deeper on Mireca Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mireca Medicines.

Explore the full profile